基因编辑权威指南。
菜单
首页 学习 新闻 向 Atlas 提问
探索 技术 疾病 治疗方法 临床试验 企业 科学家 基因 研究 机构
医学之外 农业 伦理 投资 世界地图
学习与工具 从这里开始 术语表 A–Z 对比技术 时间线 列表与排名 AI 智能体 ★ 已保存 API
关于 关于我们 方法论 数据来源 编辑方针 联系我们 免责声明

🧭 引导视图
遗传学新手?浏览时我们会用简单易懂的语言为您解释每个术语,就在同一页面内,帮助随时可用。

⚡ 专家观点
你已经了解生物学基础,只需内容本身——简洁明了,无额外解释。这是默认视图。

界面语言
浅色模式

Technology · Related approach

Gene Therapy (gene addition)

Delivers a working copy of a gene into cells without changing the existing genome — the older approach that gene editing is often confused with.

Approved DNAno editingapproved
Approved treatment At least one medicine using this approach has been authorised by a national regulator for this use.

简单说明

Gene therapy and gene editing are not the same thing, and the difference is the single most useful distinction on this site. Gene therapy adds a working copy of a gene, usually carried in by a modified virus, and leaves the broken original exactly where it is. Gene editing changes the original. Adding is older, more established, and has many approved products; changing is newer and has one.

深入了解

Gene addition delivers a functional transgene via viral vectors — adeno-associated virus for non-integrating delivery to non-dividing tissue, lentivirus for integrating delivery to dividing cells such as haematopoietic stem cells — or by non-viral means. The endogenous locus is untouched. AAV episomes dilute out as cells divide, which limits durability in proliferating tissue; lentiviral integration is durable but semi-random, carrying insertional-mutagenesis risk.

Getting the editor into a cell — the hard part AAV virus a hollowed-out virus · small cargo limit · long-lasting · immunity can block re-dosing Lipid nanoparticle a fat bubble · no size limit in practice · clears in days · naturally goes to the liver Electroporation an electric pulse · lab use, cells outside body · very efficient · only works ex vivo
Delivery, not the editing chemistry, is what decides which organs are reachable today. This is why liver diseases moved first.

Where it works better than editing

When the problem is a missing protein and the mutations causing it are scattered across the gene, adding one working copy treats everybody with the condition. Editing would need a different design per mutation. This is why approved therapies for spinal muscular atrophy, inherited retinal dystrophy and haemophilia are gene addition, not editing.

Where editing wins

When the problem is a protein that is actively harmful rather than absent — a toxic gain of function — adding another copy achieves nothing; the bad one has to be silenced or removed. Editing also preserves the gene's own regulation, which matters when the amount and timing of expression is important, and it does not run out as an AAV episome does in dividing cells.

Where editing wins
A viral capsid carrying a therapeutic gene toward a cell membrane. Illustration generated for The CRISPR Atlas — a visual aid, not a photograph or a literal depiction of molecular structure.

Common questions

What is the difference between CRISPR and gene therapy?

Gene therapy adds a working copy of a gene and leaves the faulty one in place. CRISPR gene editing changes the existing DNA itself. Both are permanent for the cells they reach, both are administered once, and in ordinary speech they get used interchangeably — but they are different interventions with different risks, and regulators treat them differently.

Sources

Connected in the Atlas

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.

与本页面相关的新闻

已自动匹配至本记录。每条条目均链接至其出版方。

First-in-human pilot trial improves stem cell collection and delivery for sickle cell gene therapy Patients with sickle cell disease are often hesitant to undergo transformative gene therapy—the current lengthy process requires multiple hospital visits… Medical Xpress — Genetics Treatments 3h ago Regenxbio hit with another clinical hold for Hunter syndrome gene therapy Regenxbio said it no longer expects to file for FDA approval of its Hunter syndrome gene therapy in the near future after the program was slapped with its… Endpoints News FDA 1d ago STAT+: Pharmalittle: We’re reading about Medicaid obesity-drug coverage, a Regenxbio gene therapy, and more President Trump’s pledge to make pricey weight loss drugs widely available for low-income Americans through Medicaid is not panning out STAT Agriculture 1d ago STAT+: FDA pauses Regenxbio gene therapy trial again due to safety concerns The FDA put a hold on a Regenxbio gene therapy trial again after new safety concerns emerged. STAT FDA 1d ago STAT+: FDA approves Ultragenyx gene therapy Regeneron wins ultra-rare disease drug approval, a validating win for mRNA research, and more biotech news from The Readout STAT FDA 5d ago STAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more A Regeneron drug for an ultra-rare disease that causes bone to grow where it shouldn't won U.S. regulatory approval, capping a three-decade effort STAT FDA 5d ago FDA approves Ultragenyx's gene therapy Genglycos for glycogen storage disorder Ultragenyx has secured its first approved gene therapy, as the FDA cleared its asset for an ultra-rare disease that can cause life-threatening blood sugar… Endpoints News FDA 5d ago Vector Production a Bottleneck for Gene Therapy Sector More effective purification materials would make viral vector production more efficient, say researchers working on an affinity adsorbent-based method… GEN — Genetic Engineering News Treatments 6d ago
仅供教育参考 本页面为参考资源,不构成医疗建议。研究进展和监管状态会发生变化;请查看上方的最后更新日期,并对重要信息进行核实,以所列主要来源为准。